Cargando…
The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determ...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950958/ https://www.ncbi.nlm.nih.gov/pubmed/35324598 http://dx.doi.org/10.3390/tropicalmed7030051 |
_version_ | 1784675268011491328 |
---|---|
author | Chae, Ganghee Choi, Aram Lim, Soyeoun Park, Sooneun Lee, Seungjun Ahn, Youngick Kim, Jinhyoung Ra, Seungwon Jegal, Yangjin Ahn, Jongjoon Park, Eunji Jun, Jaebum Kwon, Woonjung Lee, Taehoon |
author_facet | Chae, Ganghee Choi, Aram Lim, Soyeoun Park, Sooneun Lee, Seungjun Ahn, Youngick Kim, Jinhyoung Ra, Seungwon Jegal, Yangjin Ahn, Jongjoon Park, Eunji Jun, Jaebum Kwon, Woonjung Lee, Taehoon |
author_sort | Chae, Ganghee |
collection | PubMed |
description | Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determine the effectiveness of the combined use of remdesivir and regdanvimab in patients with severe COVID-19. Methods: From March to early May 2021, 124 patients with severe COVID-19 were admitted to Ulsan University Hospital (Ulsan, Korea) and received oxygen therapy and remdesivir. Among them, 25 were also administered regdanvimab before remdesivir. We retrospectively compared the clinical outcomes between the remdesivir alone group [n = 99 (79.8%)] and the regdanvimab/remdesivir group [n = 25 (20.2%)]. Results: The oxygen-free days on day 28 (primary outcome) were significantly higher in the regdanvimab/remdesivir group [mean ± SD: 19.36 ± 7.87 vs. 22.72 ± 3.66, p = 0.003]. The oxygen-free days was also independently associated with use of regdanvimab in the multivariate analysis, after adjusting for initial pulse oximetric saturation (SpO(2))/fraction of inspired oxygen (FiO(2)) ratio (severity index). Further, in the regdanvimab/remdesivir group, the lowest SpO(2)/FiO(2) ratio during treatment was significantly higher (mean ± SD: 237.05 ± 89.68 vs. 295.63 ± 72.74, p = 0.003), and the Kaplan-Meier estimates of oxygen supplementation days in surviving patients (on day 28) were significantly shorter [mean ± SD: 8.24 ± 7.43 vs. 5.28 ± 3.66, p = 0.024]. Conclusions: In patients with severe COVID-19, clinical outcomes can be improved by administering regdanvimab, in addition to remdesivir. |
format | Online Article Text |
id | pubmed-8950958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89509582022-03-26 The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study Chae, Ganghee Choi, Aram Lim, Soyeoun Park, Sooneun Lee, Seungjun Ahn, Youngick Kim, Jinhyoung Ra, Seungwon Jegal, Yangjin Ahn, Jongjoon Park, Eunji Jun, Jaebum Kwon, Woonjung Lee, Taehoon Trop Med Infect Dis Article Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determine the effectiveness of the combined use of remdesivir and regdanvimab in patients with severe COVID-19. Methods: From March to early May 2021, 124 patients with severe COVID-19 were admitted to Ulsan University Hospital (Ulsan, Korea) and received oxygen therapy and remdesivir. Among them, 25 were also administered regdanvimab before remdesivir. We retrospectively compared the clinical outcomes between the remdesivir alone group [n = 99 (79.8%)] and the regdanvimab/remdesivir group [n = 25 (20.2%)]. Results: The oxygen-free days on day 28 (primary outcome) were significantly higher in the regdanvimab/remdesivir group [mean ± SD: 19.36 ± 7.87 vs. 22.72 ± 3.66, p = 0.003]. The oxygen-free days was also independently associated with use of regdanvimab in the multivariate analysis, after adjusting for initial pulse oximetric saturation (SpO(2))/fraction of inspired oxygen (FiO(2)) ratio (severity index). Further, in the regdanvimab/remdesivir group, the lowest SpO(2)/FiO(2) ratio during treatment was significantly higher (mean ± SD: 237.05 ± 89.68 vs. 295.63 ± 72.74, p = 0.003), and the Kaplan-Meier estimates of oxygen supplementation days in surviving patients (on day 28) were significantly shorter [mean ± SD: 8.24 ± 7.43 vs. 5.28 ± 3.66, p = 0.024]. Conclusions: In patients with severe COVID-19, clinical outcomes can be improved by administering regdanvimab, in addition to remdesivir. MDPI 2022-03-18 /pmc/articles/PMC8950958/ /pubmed/35324598 http://dx.doi.org/10.3390/tropicalmed7030051 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chae, Ganghee Choi, Aram Lim, Soyeoun Park, Sooneun Lee, Seungjun Ahn, Youngick Kim, Jinhyoung Ra, Seungwon Jegal, Yangjin Ahn, Jongjoon Park, Eunji Jun, Jaebum Kwon, Woonjung Lee, Taehoon The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study |
title | The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study |
title_full | The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study |
title_fullStr | The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study |
title_full_unstemmed | The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study |
title_short | The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study |
title_sort | effectiveness of the use of regdanvimab (ct-p59) in addition to remdesivir in patients with severe covid-19: a single center retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950958/ https://www.ncbi.nlm.nih.gov/pubmed/35324598 http://dx.doi.org/10.3390/tropicalmed7030051 |
work_keys_str_mv | AT chaeganghee theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT choiaram theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT limsoyeoun theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT parksooneun theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT leeseungjun theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT ahnyoungick theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT kimjinhyoung theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT raseungwon theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT jegalyangjin theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT ahnjongjoon theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT parkeunji theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT junjaebum theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT kwonwoonjung theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT leetaehoon theeffectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT chaeganghee effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT choiaram effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT limsoyeoun effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT parksooneun effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT leeseungjun effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT ahnyoungick effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT kimjinhyoung effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT raseungwon effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT jegalyangjin effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT ahnjongjoon effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT parkeunji effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT junjaebum effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT kwonwoonjung effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy AT leetaehoon effectivenessoftheuseofregdanvimabctp59inadditiontoremdesivirinpatientswithseverecovid19asinglecenterretrospectivestudy |